Adamis pharmaceuticals says at present time, have not seen a material impact of covid-19 on demand for products

Adamis pharmaceuticals announces 2019 financial results and business update.q4 revenue $5.5 million.q4 revenue estimate $7 million -- refinitiv ibes data.adamis pharmaceuticals - at present time, have not seen a material impact of covid-19 on demand for products.adamis pharmaceuticals - have not yet seen any significant negative impact on supply chain or distribution network.adamis pharmaceuticals - have determined to postpone regularly scheduled earnings conference call.look forward to eventual approval of zimhi.symjepi sales continue to be far lower than we ever expected.cash and equivalents at end 2019 was approximately $8.8 million.in february, company increased its cash position by raising approximately $6.7 million.
ADMP Ratings Summary
ADMP Quant Ranking